Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Towards immunotherapy for peanut allergy.

Laurent Pons1, Kricia Palmer, Wesley Burks

  • 1Pediatric Allergy and Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA.

Current Opinion in Allergy and Clinical Immunology
|November 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Protocol Meets Reality.

JAMA·2026
Same author

Intradermally injected abobotulinumtoxinA administered preemptively before surgery alleviates post-surgical pain and normalizes behavior in a translational animal model.

Scientific reports·2025
Same author

Botulinum toxin intoxication requires retrograde transport and membrane translocation at the ER in RenVM neurons.

eLife·2024
Same author

WALKING BACKWARDS: REFLECTING ON THE VALUE OF MENTORS.

Transactions of the American Clinical and Climatological Association·2024
Same author

Intraoperative abobotulinumtoxinA alleviates pain after surgery and improves general wellness in a translational animal model.

Scientific reports·2022
Same author

Reply.

The Journal of allergy and clinical immunology·2022
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

New immunotherapies show promise for treating severe peanut allergies. These approaches aim to reduce allergic responses, offering hope beyond strict avoidance and epinephrine for managing this common food allergy.

Area of Science:

  • Immunology
  • Allergology
  • Gastroenterology

Background:

  • Food allergy, particularly peanut allergy, is a significant health concern causing life-threatening reactions.
  • Current management relies on strict allergen avoidance and emergency epinephrine, with limited therapeutic options.
  • Advances in understanding allergic mechanisms are driving the development of novel treatments.

Purpose of the Study:

  • To review emerging immunotherapeutic strategies for food allergy treatment and prevention.
  • To evaluate the potential of new approaches like peptide immunotherapy, mutated protein immunotherapy, DNA immunization, and anti-IgE therapy.
  • To discuss the requirements for effective and accessible food allergy therapies.

Main Methods:

  • Review of current research on immunotherapeutic strategies for food allergy.

Related Experiment Videos

  • Analysis of clinical trials for peanut allergy treatments, including anti-IgE therapy.
  • Assessment of the immunological mechanisms targeted by different therapies, such as reducing Th2 responses.

    • Main Results:

    • Several immunotherapeutic strategies, including peptide, mutated protein, and DNA-based approaches, aim to mitigate the Th2 immune response.
    • Anti-immunoglobulin E (IgE) therapy is in clinical trials for peanut allergy, preventing IgE binding and reducing symptoms.
    • Effective treatments must be well-tolerated, cost-effective, and easy to administer, potentially involving combination therapies.

    Conclusions:

    • Peanut allergy affects a substantial portion of the population, with reactions ranging from mild to fatal.
    • While strict avoidance remains the primary preventive measure, immunotherapy is expected to become a viable treatment option soon.
    • Combination therapies, potentially including anti-IgE and other immunotherapies, may offer the most effective future treatment for peanut allergy.